The Patent Finder

Terms ending in 2029

Biogen Ma Inc.

Every in-force patent on Biogen Ma Inc.'s record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 8,293,237Binding Proteins, Including Antibodies, Antibody Derivatives and Antibody Fragments, That Specifically Bind CD154 and Uses Thereof
In force
 · High confidence
Ucb Biopharma SRLIn forceHigh confidence
US D741,703Package
In force
 · High confidence
Bioverativ Therapeutics Inc.In forceHigh confidence
US 8,269,043Bicyclic Aryl Sphingosine 1-Phosphate Analogs
In force
 · High confidence
Biogen Ma Inc.In forceHigh confidence
US 9,181,191Heterobicyclic sphingosine 1-phosphate analogs
In force
 · High confidence
Biogen Ma Inc.In forceHigh confidence
US 9,708,353Heterobicyclic Sphingosine 1-Phosphate Analogs
In force
 · High confidence
Biogen Ma Inc.In forceHigh confidence
US 10,081,646Heterobicyclic Sphingosine 1-Phosphate Analogs
In force
 · High confidence
Biogen Ma Inc.In forceHigh confidence
6 of 6 patents shown. Soonest term end first, then patent number.
4 of these are in force and held by Biogen Ma Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited